Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameLaekna-B
Stock Code02105
Company Full NameTo be extracted
Industry醫療保健
Principal Activities公司成立于2016年,是一家以科學為驅動、處于臨床階段的生物醫藥科技公司。
Listing Date2023-06-29
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市浦東新區張江高科技園區蔡倫路987號5樓
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttps://www.laekna.com/
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo data

Offering Information

Offering Mechanism To be extracted
Offer PriceHK$ 12.41 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering SharesTo be extracted
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)To be confirmed
Stabilizing Manager (Greenshoe)—
Cornerstone Share86.0%
Clawback TiersTo be extracted
Reallocation OptionTo be confirmed
Total Global Offering SizeHK$ 79,088,930

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 6,205
2 lots 1,000 HK$ 12,410
3 lots 1,500 HK$ 18,615
4 lots 2,000 HK$ 24,820
5 lots 2,500 HK$ 31,025
6 lots 3,000 HK$ 37,230
7 lots 3,500 HK$ 43,435
8 lots 4,000 HK$ 49,640
9 lots 4,500 HK$ 55,845
10 lots 5,000 HK$ 62,050
12 lots 6,000 HK$ 74,460
14 lots 7,000 HK$ 86,870
16 lots 8,000 HK$ 99,280
18 lots 9,000 HK$ 111,690
20 lots 10,000 HK$ 124,100
30 lots 15,000 HK$ 186,150
40 lots 20,000 HK$ 248,200
50 lots 25,000 HK$ 310,250
60 lots 30,000 HK$ 372,300
70 lots 35,000 HK$ 434,350
80 lots 40,000 HK$ 496,400
90 lots 45,000 HK$ 558,450
100 lots 50,000 HK$ 620,500
120 lots 60,000 HK$ 744,600
140 lots 70,000 HK$ 868,700
160 lots 80,000 HK$ 992,800
200 lots 100,000 HK$ 1,241,000
400 lots 200,000 HK$ 2,482,000
600 lots 300,000 HK$ 3,723,000
800 lots 400,000 HK$ 4,964,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1,000 lots 500,000 HK$ 6,205,000
1,400 lots 700,000 HK$ 8,687,000
1,600 lots 800,000 HK$ 9,928,000
2,000 lots 1,000,000 HK$ 12,410,000
5,000 lots 2,500,000 HK$ 31,025,000
6,373 lots 3,186,500 HK$ 39,544,465

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway None
Avg Daily HK Mkt Cap ---
Est. Threshold ---
Analysis Result 无法确定入通路径

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted
First Day CloseHK$ 15.0
First Day OpenHK$ 12.44
First Day Change20.87%
First Day Volume2822000.0
First Day Turnover39083600.0
Use of Proceeds
1、約33.0%或約233.7百萬港元預計將用于迅速推進核心產品之一LAE001的臨床開發及批準; 2、約23.3%或約165.0百萬港元預計將用于推進本公司另一核心產品LAE002的臨床開發及批準; 3、約20.8%或147.4百萬港元預計將用于加快其他現有管線產品的研發,并不斷推進及改進我們的管線產品; 4、約9.9%或70.1百萬港元預計將用于提高產能及發展我們的制造能力; 5、約7.6%或53.8百萬港元預計將用于業務發展活動及增強全球網絡; 6、約5.4%或38.2百萬港元預計將用于營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Overall Coordinators (1)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Joint Bookrunners (5)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 海通国际证券有限公司 CE AAF806 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 国泰君安证券(香港)有限公司 CE ABY236 农银国际证券有限公司 CE ACX411
Joint Lead Managers (7)
CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 海通国际证券有限公司 CE AAF806 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 国泰君安证券(香港)有限公司 CE ABY236 农银国际证券有限公司 CE ACX411 富途证券国际(香港)有限公司 CE AZT137 VALUABLE CAPITAL LIMITED CE AUL711

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 OrbiMed Asia Partners III, L.P. 23,510,745 HKD — 2.98% — 6 months 2023-12-29
2 宁波姚商燕创宸凯股权投资合伙企业(有限合伙) 66,840,260 HKD — 8.45% — 6 months 2023-12-29
3 先进制造产业投资基金二期(有限合伙) 117,957,050 HKD — 14.91% — 6 months 2023-12-29
4 余姚阳明股权投资基金有限公司 471,840,610 HKD — 59.66% — 6 months 2023-12-29

Directors & Management

PositionChinese nameEnglish Name
Chairman呂向陽—
Company Secretary柯晨煜—
No director data available.

Major Shareholders

Major Shareholders & HoldingsOrbiMed Asia Partners III, L.P.(14.84%);呂向陽(12.72%);GP實體(10.49%);ESOP信托(8.75%);北京安龍實體(5.78%)
About this page

This page shows Laekna-B (02105) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect